companydata.dkcompanydata.dk

ASCENDIS PHARMA BONE DISEASES A/S: Financial statements 2015

CVR: 32323596

Source: annual report 2015, Danish Business Authority

01/01/2015 – 31/12/2015

ASCENDIS PHARMA BONE DISEASES A/S (CVR 32323596) has filed annual accounts for 2015. In 2015, the company reported a gross profit of EUR -137,219 and a net result of EUR -278,875 compared with EUR -1,336,808 the year before. Equity in the 2015 report amounted to EUR -1,939,500.

Gross Profit
EUR -137,219
Profit/Loss
EUR -278,875
Equity
EUR -1,939,500
Total Assets
EUR 240,580

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2015--137 t. EUR-279 t. EUR-1.9 mio. EUR-
2014--1.2 mio. EUR-1.3 mio. EUR-1.7 mio. EUR-
2013--4.1 mio.-4.1 mio.-4 mio.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is ASCENDIS PHARMA BONE DISEASES A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2015

ASCENDIS PHARMA BONE DISEASES A/S: The 2014 annual report is outMay 13, 2015

ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2014. Gross profit came to DKK -1,220,383, and the net result was DKK -1,336,808.

About ASCENDIS PHARMA BONE DISEASES A/S

ASCENDIS PHARMA BONE DISEASES A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S and ASCENDIS PHARMA RHEUMATOLOGY DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 229,581,000 and a net result of EUR 134,982,000 compared with EUR -139,088 the year before. Equity in the 2025 report amounted to EUR -372,183,000.

Source: annual report 2025, Danish Business Authority